This bi-monthly bulletin covers dementia and cognitive disorders including Alzheimer’s disease and dementia in Parkinson’s disease. (This issue covers 4 months)
Many of the following articles are available online via The NHS Scotland Knowledge Network. Please use the links where provided and your ATHENS password. A complete list of available online journals and registration for ATHENS can be found at www.knowledge.scot.nhs.uk
If the article you require is not available via The Knowledge Network and you would like to request a copy, please submit your request online at www.quest.scot.nhs.uk
This bulletin contains a selection of material gathered from a search of the evidence base, and is not intended to be comprehensive. Professional judgment should be exercised when appraising the material. The Library takes no responsibility for the wording, content and accuracy of the information supplied, which has been extracted in good faith from reputable sources. NHSGGC is not responsible for the content of external internet sites.
Contents Page
NEWS 2
ALZHEIMER’S DISEASE 2
DEMENTIA 9
DEMENTIA IN PARKINSON’S DISEASE 21
MILD COGNITIVE IMPAIRMENT 22
Compiled by:
Alison McAughtrie
Assistant Librarian
Western Infirmary / Gartnavel General
T: 0141 211 1856 / 0141 211 3013
E:
NEWS
The Dementia Challenge http://dementiachallenge.dh.gov.uk/
(Prime Minister’s Dementia Challenge 2020; reports on recent research; surveys and statistics; links to other dementia news)
Dementia Awareness Week news. http://www.alzscot.org/news_and_community/news/3285_dementia_awareness_week_2015
Alzheimer Scotland 2015 conference. http://daw.dementiascotland.org/conference
New publications for Allied Health Professionals (Agents of change; living well with dementia; Living well with community support). http://www.alzscot.org/news_and_community/news/3197_three_new_publications_for_allied_health_professionals
Books on prescription: dementia books in public libraries. http://alzheimers.org.uk/site/scripts/news_article.php?newsID=2303
ALZHEIMER’S DISEASE
***Hold Ctrl and click on title to check for abstract and full text – you will need to use your Athens account***
ALBERICI, A., et al, 2014. Clinical, genetic, and neuroimaging features of early onset Alzheimer disease: The challenges of diagnosis and treatment. Current Alzheimer Research, 11(10), pp. 909-917.
ALVES, JORGEMAGALHÃES, ROSANAARANTES, MAVILDECRUZ, SARAGONÇALVES,ÓSCAR F.SAMPAIO, ADRIANA, 2015. Cognitive Rehabilitation in a Visual Variant of Alzheimer's Disease. Applied Neuropsychology: Adult, 22(1), pp. 73-78.
ANNWEILER C, et al, 2015. 'Vitamin D and cognition in older adults': updated international recommendations. Journal of internal medicine, 277(1), pp. 45-57.
ANSOLEAGA, B., et al, 2015. Deregulation of purine metabolism in Alzheimer's disease. Neurobiology of aging, 36(1), pp. 68-80.
BABILONI, C., et al, 2015. Occipital sources of resting-state alpha rhythms are related to local gray matter density in subjects with amnesic mild cognitive impairment and Alzheimer's disease. Neurobiology of aging, 36(2), pp. 556-570.
BADDELEY TC, et al, 2015. Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer's disease. Journal of Pharmacology & Experimental Therapeutics, 352(1), pp. 110-118.
BAGLIO, F., et al, 2015. Multistimulation group therapy in Alzheimer’s disease promotes changes in brain functioning. Neurorehabilitation and neural repair, 29(1), pp. 13-24.
BARNES, L.L., et al, 2015. Cytomegalovirus infection and risk of alzheimer disease in older black and white individuals. Journal of Infectious Diseases, 211(2), pp. 230-237.
BENNETT DA, et al, 2015. Epigenomics of Alzheimer's disease. Translational Research: The Journal Of Laboratory & Clinical Medicine, 165(1), pp. 200-220.
BERMAN, D.E., et al, 2015. The use of pharmacological retromer chaperones in Alzheimer’s disease and other endosomal-related disorders. Neurotherapeutics, 12(1), pp. 12-18.
BERRY, J.M., et al, 2015. Perceptions of competence: Age moderates views of healthy aging and Alzheimer’s disease. Experimental aging research, 41(2), pp. 157-176.
CAGNIN, ANNACHIARACESTER, ALBERTOCOSTA, BRUNOERMANI, MARIOGABELLI,CARLOGAMBINA, GIUSEPPE, 2015. Effectiveness of switching to the rivastigmine transdermal patch from oral cholinesterase inhibitors: a naturalistic prospective study in Alzheimer's disease. Neurological Sciences, 36(3), pp. 457-463.
CALLAHAN, C.M., et al, 2015. Errors in self-reports of health services use impact on Alzheimer disease clinical trial designs. Alzheimer Disease and Associated Disorders, 29(1), pp. 75-81.
CAMARGOS, E.F., et al, 2015. Trazodone and cognitive performance in Alzheimer disease. Journal of clinical psychopharmacology, 35(1), pp. 88-89.
CARRASQUILLO, M.M., et al, 2015. Late-onset Alzheimer’s risk variants in memory decline, incident mild cognitive impairment, and Alzheimer’s disease. Neurobiology of aging, 36(1), pp. 60-67.
CHO, H., et al, 2015. Higher education affects accelerated cortical thinning in Azheimer's disease: A 5-year preliminary longitudinal study. International Psychogeriatrics, 27(1), pp. 111-120.
CIFUENTES, D., et al, 2015. Hypertension accelerates the progression of Alzheimer-like pathology in a mouse model of the disease. Hypertension, 65(1), pp. 218-224.
DONDU, A., et al, 2015. Is Obsessive-Compulsive symptomatology a risk factor for Alzheimer-type dementia?. Psychiatry research, 225(3), pp. 381-386.
EL HAJ, M., et al, 2015. Similarity between remembering the past and imagining the future in Alzheimer's disease: Implication of episodic memory. Neuropsychologia, 66, pp. 119-125.
ENACHE, D., et al, 2015. Medial temporal lobe atrophy and depressive symptoms in elderly patients with and without alzheimer disease. Journal of geriatric psychiatry and neurology, 28(1), pp. 40-48.
ESKILDSEN, S.F., et al, 2015. Structural imaging biomarkers of Alzheimer's disease: Predicting disease progression. Neurobiology of aging, 36, pp. S23-S31.
FAN H, et al, 2015. The alpha7 nAChR selective agonists as drug candidates for Alzheimer's disease. Advances in Experimental Medicine & Biology, 827, pp. 353-365.
FRENKEL, D., 2015. A new TRAIL in Alzheimer’s disease therapy. Brain: A Journal of Neurology, 138(1), pp. 8-10.
FU, Y., et al, 2015. ABCA5 regulates amyloid-β peptide production and is associated with Alzheimer’s disease neuropathology. Journal of Alzheimer's Disease, 43(3), pp. 857-869.
GALLEGO-JUTGLÀ, E., et al, 2015. A theta-band EEG based index for early diagnosis of Alzheimer's disease. Journal of Alzheimer's Disease, 43(4), pp. 1175-1184.
GOLD, B.T., 2015. Lifelong bilingualism and neural reserve against Alzheimer's disease: A review of findings and potential mechanisms. Behavioural brain research, 281, pp. 9-15.
GRAS, L., Z., et al, 2015. Balance and Gait of Adults With Very Mild Alzheimer Disease. Journal of Geriatric Physical Therapy, 38(1), pp. 1-7.
GROSSBERG, G.T., et al, 2015. Evaluating high-dose rivastigmine patch in severe Alzheimer’s disease: Analyses with concomitant memantine usage as a factor. Current Alzheimer Research, 12(1), pp. 53-60.
GROSSI, D., et al, 2015. Closing-in is related to apathy in Alzheimer’s disease patients. Journal of Alzheimer's Disease, 43(3), pp. 849-855.
GUTMAN, B.A., et al, 2015. Empowering imaging biomarkers of Alzheimer's disease. Neurobiology of aging, 36, pp. S69-S80.
HATCH, D.J., et al, 2015. Depression and antidepressant use moderate association between widowhood and Alzheimer's disease. International journal of geriatric psychiatry, 30(3), pp. 292-299.
HOGAN, D.B., 2014. Long-Term Efficacy and Toxicity of Cholinesterase Inhibitors in the Treatment of Alzheimer Disease. Canadian Journal of Psychiatry, 59(12), pp. 618-623.
INGENBLEEK, Y. and BERNSTEIN, L.H., 2015. Downsizing of lean body mass is a key determinant of Alzheimer’s disease. Journal of Alzheimer's Disease, 44(3), pp. 745-754.
JI, L., et al, 2015. Potential therapeutic implications of gelsolin in Alzheimer’s disease. Journal of Alzheimer's Disease, 44(1), pp. 13-25.
KAISER, N.C., et al, 2014. Differences in anxiety among patients with early—Versus late-onset Alzheimer's disease. The Journal of neuropsychiatry and clinical neurosciences, 26(1), pp. 73-80.
KAMAT, P.K., et al, 2014. Molecular and cellular mechanism of okadaic acid (OKA)-induced neurotoxicity: A novel tool for Alzheimer's disease therapeutic application. Molecular neurobiology, 50(3), pp. 852-865.
KANDIAH, N.C., 2015. Association between white matter hyperintensity and medial temporal atrophy at various stages of Alzheimer's disease. European Journal of Neurology, 22(1), pp. 150-155.
KARCH, C.M. and GOATE, A.M., 2015. Alzheimer’s disease risk genes and mechanisms of disease pathogenesis. Biological psychiatry, 77(1), pp. 43-51.
KHEDHER, L., et al, 2015. Early diagnosis of Alzheimer's disease based on partial least squares, principal component analysis and support vector machine using segmented MRI images. Neurocomputing: An International Journal, 151, pp. 139-150.
KOUNTOURAS, J.G., 2014. Association between Helicobacter pylori burden and Alzheimer's disease. European Journal of Neurology, 21(12), pp. e100-e100.
LALANNE, J., et al, 2015. 'The Castle of Remembrance': New insights from a cognitive training programme for autobiographical memory in Alzheimer's disease. Neuropsychological Rehabilitation, 25(2), pp. 254-282.
LAN, Y., et al, 2015. Update on the neuroprotective effect of estrogen receptor alpha against Alzheimer's disease. Journal of Alzheimer's Disease, 43(4), pp. 1137-1148.
LANCIONI, G.E., et al, 2015. Persons with Alzheimer's disease engage in leisure and mild physical activity with the support of technology-aided programs. Research in developmental disabilities, 37, pp. 55-63.
LEAVITT, F. and KATZ, R.S., 2015. Cross-sectional neurocognitive data do not support a transition from fibrofog to alzheimer disease in fibromyalgia patients. Journal of Clinical Rheumatology, 21(2), pp. 81-85.
LEE, Y.H. and SONG, G.G., 2015. Genome-wide pathway analysis of a genome-wide association study on Alzheimer’s disease. Neurological Sciences, 36(1), pp. 53-59.
LEFORT, R., 2015. Reversing synapse loss in Alzheimer’s disease: Rho-guanosine triphosphatases and insights from other brain disorders. Neurotherapeutics, 12(1), pp. 19-28.
LIANG, L. and WEI, H., 2015. Dantrolene, a treatment for Alzheimer disease?. Alzheimer Disease and Associated Disorders, 29(1), pp. 1-5.
LORENZI, M., et al, 2015. Disentangling normal aging from Alzheimer's disease in structural magnetic resonance images. Neurobiology of aging, 36, pp. S42-S52.
LORIUS, N., et al, 2015. Vascular disease and risk factors are associated with cognitive decline in the Alzheimer disease spectrum. Alzheimer Disease and Associated Disorders, 29(1), pp. 18-25.
LOWE, D.A., et al, 2015. Misconceptions of Alzheimer’s disease. Clinical Gerontologist: The Journal of Aging and Mental Health, 38(2), pp. 149-156.
MACHADO, A., et al, 2014. Chronic stress as a risk factor for Alzheimer’s disease. Reviews in the neurosciences, 25(6), pp. 785-804.
MANNI, R.S., 2015. Sleep continuity scale in Alzheimer's disease (SCADS): application in daily clinical practice in an Italian center for dementia. Neurological Sciences, 36(3), pp. 469-471.
MARTISKAINEN, H., et al, 2015. Effects of Alzheimer's disease-associated risk loci on cerebrospinal fluid biomarkers and disease progression: A polygenic risk score approach. Journal of Alzheimer's Disease, 43(2), pp. 565-573.
MASTERS, M.C., et al, 2015. "Noncognitive" symptoms of early Alzheimer disease : A longitudinal analysis. Neurology, 84(6), pp. 617-622.
MENCHOLA, M.,BARRY D., 2015. Addressing Alzheimer's: A pragmatic approach. Journal of Family Practice, 64(1), pp. 10-18.
MING, J., et al, 2015. Integrated cortical structural marker for Alzheimer’s disease. Neurobiology of aging, 36, pp. S53-S59.
MOLITOR, R.J., et al, 2015. Eye movements in Alzheimer’s disease. Journal of Alzheimer's Disease, 44(1), pp. 1-12.
MORENO-TREVINO, M.G., et al, 2015. Moving away from amyloid beta to move on in Alzheimer research.
MORMONT, E., et al, 2014. Symptoms of depression and anxiety after the disclosure of the diagnosis of Alzheimer disease. Journal of geriatric psychiatry and neurology, 27(4), pp. 231-236.
NOLAN, J.M., et al, 2015. The impact of supplemental macular carotenoids in Alzheimer's disease: A randomized clinical trial. Journal of Alzheimer's Disease, 44(4), pp. 1157-1169.
PERRY, D., et al, 2015. Building a roadmap for developing combination therapies for Alzheimer’s disease. Expert Review of Neurotherapeutics, 15(3), pp. 327-333.
PETER-DEREX, L., et al, 2015. Sleep and Alzheimer's disease. Sleep Medicine Reviews, 19, pp. 29-38.
PIACERI, I., et al, 2015. Epigenetic modifications in Alzheimer's disease: Cause or effect? Journal of Alzheimer's Disease, 43(4), pp. 1169-1173.
PISA, D., et al, 2015. Direct visualization of fungal infection in brains from patients with Alzheimer's disease. Journal of Alzheimer's Disease, 43(2), pp. 613-624.
PIVTORAIKO, V.N., et al, 2015. Cortical pyroglutamate amyloid-β levels and cognitive decline in Alzheimer's disease. Neurobiology of aging, 36(1), pp. 12-19.
PRAKASH, A., et al, 2015. Pharmacological approaches for Alzheimer’s disease: Neurotransmitter as drug targets. Expert Review of Neurotherapeutics, 15(1), pp. 53-71.
ROSALES-CORRAL, S., et al, 2015. Diabetes and alzheimer disease, two overlapping pathologies with the same background: Oxidative stress. Oxidative Medicine and Cellular Longevity, 2015
ROSENBLOOM, MICHAELBARCLAY, TERRYPYLE, MARIAOWENS, BRIANCAGAN, AMANDAANDERSON, CHRISTOPHERFREY,WILLIAMHANSON, LEAH, 2014. A Single-Dose Pilot Trial of Intranasal Rapid-Acting Insulin in Apolipoprotein E4 Carriers with Mild-Moderate Alzheimer's Disease. CNS Drugs, 28(12), pp. 1185-1189.
SALZMAN, C. and SHADER, R.I., 2015. Benzodiazepine use and risk for Alzheimer disease. Journal of clinical psychopharmacology, 35(1), pp. 1-3.
SEIDL, J.N.T. and MASSMAN, P.J., 2015. Relationships between testosterone levels and cognition in patients with alzheimer disease and nondemented elderly men. Journal of geriatric psychiatry and neurology, 28(1), pp. 27-39.
SEKAR, S., et al, 2015. Alzheimer's disease is associated with altered expression of genes involved in immune response and mitochondrial processes in astrocytes. Neurobiology of aging, 36(2), pp. 583-591.
SHEA, T.B. and REMINGTON, R., 2015. Nutritional supplementation for Alzheimer's disease? Current Opinion in Psychiatry, 28(2), pp. 141-147.
STARGARDT, A., et al, 2015. The storm before the quiet: Neuronal hyperactivity and Aβ in the presymptomatic stages of Alzheimer's disease. Neurobiology of aging, 36(1), pp. 1-11.
STEPHENSON, D., 2015. Alzheimer’s disease: Current and future therapy. Expert Review of Neurotherapeutics, 15(1), pp. 1-2.
STEPHENSON, D., et al, 2015. Charting a path toward combination therapy for Alzheimer’s disease. Expert Review of Neurotherapeutics, 15(1), pp. 107-113.
STONE, J., et al, 2015. The mechanical cause of age-related dementia (Alzheimer’s disease): The brain is destroyed by the pulse. Journal of Alzheimer's Disease, 44(2), pp. 355-373.
SZUTOWICZ, A., et al, 2015. Retinoic acid as a therapeutic option in Alzheimer’s disease: A focus on cholinergic restoration. Expert Review of Neurotherapeutics, 15(3), pp. 239-249.
TATENO, A., et al, 2015. A case of Alzheimer's disease following mild traumatic brain injury. Netherlands: Elsevier Science.
THAL, D.R. and FÄNDRICH, M., 2015. Protein aggregation in Alzheimer’s disease: Aβ and τ and their potential roles in the pathogenesis of AD. Acta Neuropathologica, 129(2), pp. 163-165.
THAL, D.R., et al, 2015. Neuropathology and biochemistry of Aβ and its aggregates in Alzheimer’s disease. Acta Neuropathologica, 129(2), pp. 167-182.
TRAYNOR, B.J. and RENTON, A.E., 2015. Exploring the epigenetics of Alzheimer disease. JAMA Neurology, 72(1), pp. 8-9.
VARDARAJAN, B.N., et al, 2015. Coding mutations in SORL1 and Alzheimer disease. Annals of Neurology, 77(2), pp. 215-227.